Celldex Therapeutics, Inc. (CLDX)
CLDX Stock Price Chart
Explore Celldex Therapeutics, Inc. interactive price chart. Choose custom timeframes to analyze CLDX price movements and trends.
CLDX Company Profile
Discover essential business fundamentals and corporate details for Celldex Therapeutics, Inc. (CLDX) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
15 May 1986
Employees
186.00
Website
https://www.celldex.comCEO
Anthony S. Marucci
Description
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-0159, a Phase I monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity; CDX-1140, a human agonist monoclonal antibody targeted to CD40, a key activator of immune response, which is found on dendritic cells, macrophages, and B cells, as well as is expressed on various cancer cells; and CDX-527, a bispecific antibody, which uses the company's proprietary active anti-PD-L1 and CD27 human antibodies to couple CD27 costimulation with blockade of the PD-L1/PD-1 pathway to help prime and activate anti-tumor T cell responses through CD27 costimulation. The company has research collaboration and license agreements with University of Southampton to develop human antibodies towards CD27; Amgen Inc. with exclusive rights to CDX-301 and CD40 ligand; and Yale University. Celldex Therapeutics, Inc. was incorporated in 1983 and is headquartered in Hampton, New Jersey.
CLDX Financial Timeline
Browse a chronological timeline of Celldex Therapeutics, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 6 May 2026
Upcoming earnings on 25 Feb 2026
Upcoming earnings on 5 Nov 2025
EPS estimate is -$0.90, while revenue estimate is $1.18M.
Earnings released on 7 Aug 2025
EPS came in at -$0.85 surpassing the estimated -$0.86 by +1.16%, while revenue for the quarter reached $730.00K , missing expectations by -38.34%.
Earnings released on 8 May 2025
EPS came in at -$0.81 falling short of the estimated -$0.75 by -8.00%, while revenue for the quarter reached $695.00K , missing expectations by -37.99%.
Earnings released on 27 Feb 2025
EPS came in at -$0.71 surpassing the estimated -$0.73 by +2.74%, while revenue for the quarter reached $1.18M , missing expectations by -6.15%.
Earnings released on 6 Nov 2024
EPS came in at -$0.64 surpassing the estimated -$0.69 by +7.25%, while revenue for the quarter reached $3.19M , beating expectations by +192.75%.
Earnings released on 8 Aug 2024
EPS came in at -$0.54 surpassing the estimated -$0.59 by +8.47%, while revenue for the quarter reached $2.50M , beating expectations by +204.63%.
Earnings released on 6 May 2024
EPS came in at -$0.56 surpassing the estimated -$0.67 by +16.42%, while revenue for the quarter reached $156.00K , missing expectations by -83.04%.
Earnings released on 26 Feb 2024
EPS came in at -$0.57 surpassing the estimated -$0.76 by +25.00%, while revenue for the quarter reached $4.13M , beating expectations by +391.79%.
Earnings released on 2 Nov 2023
EPS came in at -$0.81 falling short of the estimated -$0.67 by -20.90%, while revenue for the quarter reached $1.52M , beating expectations by +64.89%.
Earnings released on 8 Aug 2023
EPS came in at -$0.65 matching the estimated -$0.65, while revenue for the quarter reached $268.00K , missing expectations by -49.43%.
Earnings released on 4 May 2023
EPS came in at -$0.62 surpassing the estimated -$0.63 by +1.59%, while revenue for the quarter reached $967.00K , beating expectations by +135.85%.
Earnings released on 28 Feb 2023
EPS came in at -$0.56 surpassing the estimated -$0.59 by +5.08%, while revenue for the quarter reached $1.61M , beating expectations by +510.98%.
Earnings released on 9 Nov 2022
EPS came in at -$0.57 matching the estimated -$0.57, while revenue for the quarter reached $407.00K , beating expectations by +13.06%.
Earnings released on 8 Aug 2022
EPS came in at -$0.58 falling short of the estimated -$0.43 by -34.88%, while revenue for the quarter reached $163.00K , missing expectations by -59.25%.
Earnings released on 5 May 2022
EPS came in at -$0.49 falling short of the estimated -$0.46 by -6.52%, while revenue for the quarter reached $174.00K , missing expectations by -68.93%.
Earnings released on 28 Feb 2022
EPS came in at -$0.43 falling short of the estimated -$0.42 by -2.38%, while revenue for the quarter reached $333.00K , missing expectations by -67.86%.
Earnings released on 9 Nov 2021
EPS came in at -$0.39 falling short of the estimated -$0.35 by -11.43%, while revenue for the quarter reached $153.00K , missing expectations by -76.09%.
Earnings released on 5 Aug 2021
EPS came in at -$0.34 surpassing the estimated -$0.40 by +15.00%, while revenue for the quarter reached $3.48M , beating expectations by +408.03%.
Earnings released on 6 May 2021
EPS came in at -$0.42 falling short of the estimated -$0.32 by -31.25%, while revenue for the quarter reached $685.00K , beating expectations by +14.17%.
Earnings released on 29 Mar 2021
EPS came in at -$0.26 surpassing the estimated -$0.37 by +29.73%, while revenue for the quarter reached $3.79M .
Earnings released on 5 Nov 2020
EPS came in at -$0.36 falling short of the estimated -$0.34 by -5.88%, while revenue for the quarter reached $668.00K , meeting expectations.
CLDX Stock Performance
Access detailed CLDX performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.